What question did this study set out to answer?

This analysis aims to evaluate treatment persistence and switching patterns among IBD patients receiving advanced therapies.

P0750Therapy courses of advanced therapies for Inflammatory Bowel Disease (IBD): results from the TARGET register for patients with IBD in Germany

View Full Paper

Ask AI

Bookmark

This analysis aims to evaluate treatment persistence and switching patterns among IBD patients receiving advanced therapies.
Data collection via the TARGET registry, a multicenter, non-interventional cohort study.
Included 1764 IBD patients from Germany, collecting data every 6 months.
Used Kaplan-Meier analysis to assess treatment persistence over 10 years.
Applied Chi2-test to compare persistence rates across different therapeutic groups.
2001 therapy courses were analyzed, with significant discrepancies in therapy switches between advanced therapies.
Treatment persistence rates after 10 years ranged from 83% to 93% across different therapies.
A majority of patients who switched therapies moved from anti-TNF to newer therapies, with 17% remaining within the anti-TNF group.

No takes yet. Share an insight, caveat, or question.

A multicenter cohort study analyzes treatment persistence and switching patterns in IBD patients, suggesting high retention rates across therapies.

Plachta-Danielzik et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

A multicenter cohort study analyzes treatment persistence and switching patterns in IBD patients, suggesting high retention rates across therapies.